Estimated Cost Savings with Provision of Vaccinations

Estimated Human and Economic Burden of Four Major Adult Vaccine-Preventable
Diseases in the United States, 2013

 

Using data from the peer-reviewed literature, government disease-surveillance programs, and the US Census, authors developed a customizable model to estimate human and economic burden caused by four major adult vaccine-preventable diseases in 2013 in
the United States.

Estimated medical costs per case:

  • Influenza

    • >50 yo: $1571

    • >65 yo: $1867

  • Pneumococcal (non-bacteremic pneumococcal pneumonia)

    • Inpatient >50 yo: $15335

    • Inpatient >65 yo: $15221

    • Outpatient >50 yo: $676

    • Outpatient >65 yo: $721

  • Herpes zoster

    • >50 yo: $1974

    • >65 yo: $2354

  • Pertussis

  • >50 yo: $432

  • >65 yo: $432

Evaluation of the Cost-Effectiveness in the
United States of a Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults

 

An evaluation of cost-effectiveness to support the vaccination of
immunocompetent Americans aged ≥60 years was performed. The study showed that the herpes zoster vaccine could eliminate thousands of cases of herpes zoster, hospitalizations, and prescriptions in vaccinated adults.

A savings of $82 million to $103
million in healthcare costs associated with the diagnosis and treatment of herpes zoster, postherpetic neuralgia, and other complications associated
with herpes zoster

  • Cost per QALY gained (payer
    perspective): $18,439 (cost savings of $50,232)

Screen Shot 2019-07-08 at 4.57.00 PM.png
  • White Instagram Icon

@actforpharmacy

#ACTforPharmacy

Proudly created with Wix.com

Email: 

actforpharmacy@pitt.edu

Address:

ACT Pharmacy Collaborative

University of Pittsburgh School of Pharmacy

5607 Baum Blvd., Room 303

Pittsburgh, PA 15206